molecules-logo

Journal Browser

Journal Browser

Application of Novel Method in Pharmaceutical Study II

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 8672

Special Issue Editors

Department of Biopharmaceutics, School of Life Sciences, Jilin University, No.2699, Qianjin Street, Changchun 130012, China
Interests: novel drug delivery system; innovative technologies; microfluidic; targeted therapy; nanotechnology
Special Issues, Collections and Topics in MDPI journals
Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: nanotechnology; novel nanocarrier; gene therapy; immunotherapy

Special Issue Information

Dear Colleagues,

With the improvements in medical treatment levels, the prevention and treatment of diseases that are difficult to cure have made important progress. Currently, a wide variety of drug formulations and technologies have been explored in malignant tumors, cardio cerebral vascular disease, anti-infection, geriatric diseases, etc. However, a number of problems still need to be solved before their utilization can become routine. These issues include low solubility, poor penetration into cells, hepatic disposition, narrow therapeutic index, rapid uptake by normal tissues, low bioavailability and high costs. Additionally, therapeutic drugs may have unfavorable pharmacokinetic parameters, such as a fast clearance rate and short terminal elimination half-life. Moreover, the emergence of drug resistance involving multiple mechanisms is a major obstacle to successful application in clinics. Therefore, in order to solve these problems, various novel strategies must be applied to pharmaceutical research. These methods include: Nanotechnology for the delivery of drugs, active targeting delivery of drugs for diseases therapy, scientific application of polymer materials and molecular biological methods, and so on. 

The purpose of this Special Issue is to present a series of application of novel methods in pharmaceutical study. We are committed to acquiring high-tech drugs that are fixed-time, fixed-position, and quantitative release. We hope these novel methods can help us overcome all the obstacles above.

Prof. Dr. Lesheng Teng
Dr. Zhaogang Yang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Nanotechnology
  • Targeted therapy
  • Novel nanocarrier
  • Gene therapy
  • Immunotherapy
  • Polymer materials

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 3533 KiB  
Article
Amphotericin B and Curcumin Co-Loaded Porous Microparticles as a Sustained Release System against Candida albicans
by Baiji Xue, Yanhua Yu, Guoqiang Peng, Mengmeng Sun, Peng Lv and Xuefeng Li
Molecules 2022, 27(10), 3079; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules27103079 - 11 May 2022
Cited by 3 | Viewed by 1501
Abstract
Amphotericin B (AMB) is an antifungal drug used for serious fungal infections. However, AMB has adverse reactions such as nephrotoxicity, which limit the clinical application of AMB alone or in combination with other antifungal drugs. Nano or micro drug delivery systems (DDS) have [...] Read more.
Amphotericin B (AMB) is an antifungal drug used for serious fungal infections. However, AMB has adverse reactions such as nephrotoxicity, which limit the clinical application of AMB alone or in combination with other antifungal drugs. Nano or micro drug delivery systems (DDS) have been proven to be effective in reducing the toxic and side effects of drugs. Further, the combination of AMB with other compounds with antifungal activity, such as curcumin (CM), may enhance the synergistic effects. Herein, AMB and CM were co-loaded into porous poly (lactic-co-glycolic acid) (PLGA) microparticles (MPs) to prepare AMB/CM-PLGA MPs. The AMB/CM-PLGA MPs showed a remarkably reduced hemolysis (62.2 ± 0.6%) compared to AMB (80.9 ± 1.1%). The nephrotoxicity of AMB/CM-PLGA MPs is significantly lower than that of AMB. In vitro, AMB/CM-PLGA MPs had better inhibitory effects on the adhesion and biofilm formation of Candida albicans compared with AMB. Experiments on mice infected with C. albicans showed that AMB/CM-PLGA MPs have a better therapeutic effect than AMB in vivo. In summary, AMB/CM-PLGA MPs may be a novel and promising therapeutic candidate for fungal infection. Full article
(This article belongs to the Special Issue Application of Novel Method in Pharmaceutical Study II)
Show Figures

Figure 1

Review

Jump to: Research

29 pages, 2169 KiB  
Review
Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy
by Chi Zhang, Yifan Ma, Jingjing Zhang, Jimmy Chun-Tien Kuo, Zhongkun Zhang, Haotian Xie, Jing Zhu and Tongzheng Liu
Molecules 2022, 27(6), 1943; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules27061943 - 17 Mar 2022
Cited by 25 | Viewed by 6722
Abstract
Lipid-based nanoparticles (LBNPs) are biocompatible and biodegradable vesicles that are considered to be one of the most efficient drug delivery platforms. Due to the prominent advantages, such as long circulation time, slow drug release, reduced toxicity, high transfection efficiency, and endosomal escape capacity, [...] Read more.
Lipid-based nanoparticles (LBNPs) are biocompatible and biodegradable vesicles that are considered to be one of the most efficient drug delivery platforms. Due to the prominent advantages, such as long circulation time, slow drug release, reduced toxicity, high transfection efficiency, and endosomal escape capacity, such synthetic nanoparticles have been widely used for carrying genetic therapeutics, particularly nucleic acids that can be applied in the treatment for various diseases, including congenital diseases, cancers, virus infections, and chronic inflammations. Despite great merits and multiple successful applications, many extracellular and intracellular barriers remain and greatly impair delivery efficacy and therapeutic outcomes. As such, the current state of knowledge and pitfalls regarding the gene delivery and construction of LBNPs will be initially summarized. In order to develop a new generation of LBNPs for improved delivery profiles and therapeutic effects, the modification strategies of LBNPs will be reviewed. On the basis of these developed modifications, the performance of LBNPs as therapeutic nanoplatforms have been greatly improved and extensively applied in immunotherapies, including infectious diseases and cancers. However, the therapeutic applications of LBNPs systems are still limited due to the undesirable endosomal escape, potential aggregation, and the inefficient encapsulation of therapeutics. Herein, we will review and discuss recent advances and remaining challenges in the development of LBNPs for nucleic acid-based immunotherapy. Full article
(This article belongs to the Special Issue Application of Novel Method in Pharmaceutical Study II)
Show Figures

Figure 1

Back to TopTop